Dr.Neil Bayman – Best Costs, Reviews – Book Your Consultation

Professional Experience

• Joined The Christie in 2009 as Consultant Clinical Oncologist specialising in lung cancer
• Appointed Executive Medical Director in November 2021 (after serving as interim and Associate Medical Director roles)
• Between 2014 and 2017, served as inaugural Clinical Director for Lung Cancer within the Greater Manchester Cancer Alliance, driving pathway transformation and multidisciplinary working
• Held national advisory roles: Specialist Advisor for Oncology to the Care Quality Commission, member of NHS England’s chemotherapy reference groups, participant in lung cancer expert and clinical oncology boards
• Continues a clinical practice alongside leadership responsibilities

Academic Contributions

• Active contributor to lung cancer and thoracic radiotherapy research
• Published more than 150 peer-reviewed papers, many in lung cancer radiotherapy, toxicity outcomes, and novel treatment techniques (via ResearchGate)
• Serves on national radiotherapy, clinical oncology and lung cancer professional committees and standard-setting groups
• Mentor and educator for junior oncologists and trainees in radiotherapy and thoracic oncology

Areas of Expertise

• Lung cancer radiotherapy: curative-intent, palliative, stereotactic ablative radiotherapy (SABR)
• Thoracic oncology care including mesothelioma and combined modality treatment (chemoradiation)
• Research in treatment toxicity, dose optimization, and improving patient outcomes
• Integration of electronic patient-reported outcomes (ePROMs) into routine care to monitor symptoms, side effects, and quality of life

Publications and Research

Patient Care Philosophy

• Clear communication: providing understandable explanations of complex radiotherapy plans, side effects, risks and benefits
• Shared decision-making: involving patients in choices about their treatment trajectories
• Balancing treatment efficacy with quality of life, especially in advanced lung disease and comorbidity settings
• Using patient-reported symptom tracking to guide adaptive care and early intervention
• Maintaining service quality, safety, and continuous improvement even while fulfilling leadership roles

Professional Affiliations

• Fellow of the Royal College of Radiologists (FRCR)
• Member of the Royal College of Physicians (MRCP)
• Member of NHS England lung cancer expert groups and chemotherapy reference panels
• Advisor roles with the Care Quality Commission in oncology
• Participant in national clinical oncology regional and specialty boards and standard-setting committees

FAQs

Is Dr Neil Bayman board-certified?

Yes — he holds FRCR and MRCP credentials and is an accredited Consultant Clinical Oncologist in the UK.

What cancers does he treat?

His primary focus is lung cancer and mesothelioma, delivering radiotherapy and combined treatments to thoracic malignancies.

Does Dr Bayman treat international patients?

His primary practice is within The Christie NHS and private care pathways, which may accept international referrals based on capacity and agreements.

How long is a typical radiotherapy course?

It varies: curative radiotherapy regimens may span several weeks; stereotactic ablative radiotherapy (SABR) may use fewer high-dose sessions.

What languages does he speak?

His professional language is English; public sources do not list additional languages.

Is Dr Bayman still active in academic research?

Yes — he continues to publish research in lung cancer radiotherapy, participates in trials, and contributes to professional guideline development.

What leadership roles does he hold?

He is Executive Medical Director at The Christie, previously associate and interim medical director, and previously served as Clinical Director for Lung Cancer in Greater Manchester.